A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

NCT06234137 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm Female

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Inetetamab
DRUG: Pyrotinib

Sponsor

Wang Ouchen